Wegovy

Mar 26, 2025

Obesity is a chronic disease reaching alarming levels worldwide, leading to diabetes, cardiovascular disease, and metabolic disorders. It results from a mix of genetic, environmental, and lifestyle factors. Understanding what are the reasons for obesity—poor diet, inactivity, and hormonal imbalances—is crucial. Key...

Mar 17, 2025

The global obesity crisis has sparked a multibillion-dollar showdown in the pharmaceutical world, with Novo Nordisk and Eli Lilly locked in an intense battle for supremacy. These industry titans are redefining the weight loss drug market with groundbreaking GLP-1 therapies. Novo Nordisk’s WEGOVY (semaglutide) and E...

Mar 12, 2025

Obesity ranks as the second leading cause of preventable death, linked to the risk of inflammatory conditions that are directly and indirectly related to cardiovascular disease, diabetes, respiratory issues, psychological problems, hypertension, obstructive sleep apnea, cancer, and hyperlipidemia. This poses a majo...

Mar 12, 2025

With the growing global health concern regarding obesity, Novo’s WEGOVY (semaglutide) has emerged as a leading solution in the weight loss treatment market. WEGOVY is a GLP-1 receptor agonist used alongside a low-calorie diet and increased physical activity. This obesity medication is administered as a weekly subcu...

Mar 12, 2025

Obesity is the second leading cause of preventable death and is linked to numerous inflammatory conditions, which contribute to diseases like cardiovascular disease, diabetes, respiratory issues, mental health disorders, hypertension, obstructive sleep apnea, cancer, and high cholesterol. This poses a significant p...

Mar 11, 2025

Neurotech’s ENCELTO Becomes First FDA-Approved Treatment for Macular Telangiectasia Type 2 Neurotech Pharmaceuticals, Inc. has announced that the FDA has approved ENCELTO (revakinagene taroretcel-lwey) for the treatment of Macular Telangiectasia type 2 (MacTel), a progressive neurodegenerative retinal disease th...

Feb 03, 2025

The recent approval of OZEMPIC reinforces the growing trend of GLP-1 drugs being used for conditions beyond diabetes and weight loss. Novo Nordisk’s blockbuster GLP-1 medication, OZEMPIC, has secured another label expansion, as the FDA has now approved it for treating chronic kidney disease. The approval for chr...

Jan 06, 2025

Eli Lilly’s blockbuster weight loss GLP-1 drug ZEPBOUND has received FDA approval to treat obstructive sleep apnea in adults with obesity, alongside diet and exercise. This marks the first FDA-approved medication for obstructive sleep apnea.  The approval adds a second indication for ZEPBOUND, following its...

Aug 09, 2024

More than 80 obesity drugs are currently in the pipeline with a strong emphasis on GLP-1 receptor agonists. Glucagon-like peptide-1 (GLP-1) receptor agonists are medications designed to treat type 2 diabetes mellitus and obesity by reducing blood glucose levels and regulating metabolism. Ongoing efforts by several ...

Mar 12, 2024

BeiGene Receives FDA Accelerated Approval for BRUKINSA in Relapsed/Refractory Follicular Lymphoma BeiGene, Ltd., has declared that the FDA has provided accelerated approval for BRUKINSA® (zanubrutinib) to be used in treating adult patients with relapsed or refractory (R/R) follicular lymphoma (FL), when used alo...